{"id":3207,"date":"2025-07-23T09:30:00","date_gmt":"2025-07-23T08:30:00","guid":{"rendered":"https:\/\/patworld.com\/gb\/?p=3207"},"modified":"2026-01-05T15:41:09","modified_gmt":"2026-01-05T15:41:09","slug":"ross-cummings-biotech-patent-innovation","status":"publish","type":"post","link":"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/","title":{"rendered":"Meet the IP Professional: Ross Cummings \u2013 Leading the Charge in Life Sciences Innovation\u00a0"},"content":{"rendered":"\n<p>At the forefront of biotech patenting and innovation sits <a href=\"https:\/\/www.linkedin.com\/in\/rosscummingsgje\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ross Cummings<\/a>, a partner at <a href=\"https:\/\/www.gje.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Gill Jennings &amp; Every LLP (GJE)<\/a>, whose career has been shaped by scientific rigor, a deep commitment to clients, and a passion for future-forward technologies. With a PhD in molecular biology from the London School of Hygiene and Tropical Medicine and nearly two decades of IP experience under his belt, Ross brings a rare fusion of technical depth and commercial strategy to one of the most fast-moving areas in intellectual property: cellular immunotherapy and RNA-based technologies. PatWorld sat down with Ross to discuss recent data relating to cellular immunotherapy, as well as his career journey, strategic insights, and the trends shaping the future of biotech IP.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>From the Lab Bench to the Patent Bar<\/strong>&nbsp;<\/h2>\n\n\n\n<p>Ross\u2019s journey into the world of patents began during his doctoral work on malaria enzymes. It was then that a Japanese patent, offering unexpected insights into his research, altered the trajectory of his thesis\u2014and eventually his career. \u201cIt gave me the tools to push my research forward,\u201d Ross reflects. \u201cThat was my first exposure to the value of patents\u2014not just as legal instruments, but as sources of technical knowledge.\u201d&nbsp;<\/p>\n\n\n\n<p>Since then, Ross has become a trusted adviser to biotech innovators, working with companies across the UK, Europe, the US, and Asia. His experience spans everything from gene therapies and diagnostics to CRISPR and synthetic biology.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Navigating the Patent Boom in Cell and Gene Therapies<\/strong>&nbsp;<\/h2>\n\n\n\n<p>Ross\u2019s enthusiasm for biotech is palpable, particularly when discussing the renaissance in RNA and cell therapies. \u201cWe\u2019re in a period of rapid acceleration,\u201d he says. \u201cCOVID-19 changed everything. It proved RNA technologies could be safe, fast, and effective, and that opened the floodgates.\u201d&nbsp;<\/p>\n\n\n\n<p>The data backs this up. Landscape charts generated by PatWorld show a sharp rise in first-priority patent filings over the past decade in cellular immunotherapy\u2014a trend Ross believes is sustainable, provided financing remains strong. \u201cWe feel very busy, and that\u2019s usually a good indicator,\u201d he notes.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"602\" height=\"444\" data-src=\"https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/Figure-1-First-Priority-Year-1.png\" alt=\"\" class=\"wp-image-3217 lazyload\" data-srcset=\"https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/Figure-1-First-Priority-Year-1.png 602w, https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/Figure-1-First-Priority-Year-1-300x221.png 300w, https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/Figure-1-First-Priority-Year-1-24x18.png 24w, https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/Figure-1-First-Priority-Year-1-36x27.png 36w, https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/Figure-1-First-Priority-Year-1-48x35.png 48w\" data-sizes=\"(max-width: 602px) 100vw, 602px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 602px; --smush-placeholder-aspect-ratio: 602\/444;\" \/><\/figure>\n\n\n\n<p><em>Figure 1: First Priority Year<\/em> (see Landscape Charts)&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Global Trends and Shifting Hubs<\/strong>&nbsp;<\/h2>\n\n\n\n<p>When reviewing Figure 2, which maps first-priority countries, Ross notes the dominant presence of the US in this space. \u201cThat\u2019s not surprising\u2014the US biotech scene has much deeper funding,\u201d he comments. \u201cBut the UK is punching above its weight, even if some of that activity is driven by a handful of companies.\u201d&nbsp;<\/p>\n\n\n\n<p>He also points to China\u2019s rapidly growing interest in antibodies and biologics. \u201cWe\u2019re seeing more biotech filings from China, and companies there are now licensing innovations back to US pharma firms. That\u2019s a shift worth watching.\u201d<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"602\" height=\"437\" data-src=\"https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/Figure-2-1st-Priority-Country.png\" alt=\"\" class=\"wp-image-3218 lazyload\" data-srcset=\"https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/Figure-2-1st-Priority-Country.png 602w, https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/Figure-2-1st-Priority-Country-300x218.png 300w, https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/Figure-2-1st-Priority-Country-24x17.png 24w, https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/Figure-2-1st-Priority-Country-36x26.png 36w, https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/Figure-2-1st-Priority-Country-48x35.png 48w\" data-sizes=\"(max-width: 602px) 100vw, 602px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 602px; --smush-placeholder-aspect-ratio: 602\/437;\" \/><\/figure>\n\n\n\n<p><em>Figure 2: 1st Priority Country<\/em> (see Landscape Charts)&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Strategic IP in a Crowded Landscape<\/strong>&nbsp;<\/h2>\n\n\n\n<p>For biotech start-ups working in competitive areas like RNA or CAR-T therapies, Ross stresses the importance of early, robust data. \u201cThe patent system is shifting\u2014strong experimental support is more important than ever,\u201d he explains.&nbsp;<\/p>\n\n\n\n<p>He also encourages companies to embrace flexibility: \u201cA narrow claim might still be powerful in biotech, especially if it directly protects your approved product. It&#8217;s about tailoring your IP strategy to your development path.\u201d&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Human Element in High-Stakes Innovation<\/strong>&nbsp;<\/h2>\n\n\n\n<p>Ross is especially motivated by the potential of these therapies to transform lives\u2014particularly for children with rare diseases. \u201cFor the first time in history, many of these genetic conditions have real hope,\u201d he says, adding that early screening and fast action can make all the difference.&nbsp;<\/p>\n\n\n\n<p>He also sees platform technologies and adaptable delivery mechanisms as crucial to expanding access to these innovations, both scientifically and commercially.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Looking Ahead: Synthetic Biology and Sustainability<\/strong>&nbsp;<\/h2>\n\n\n\n<p>Beyond therapeutics, Ross is enthusiastic about the future of synthetic biology. \u201cWe\u2019re approaching a time where we can manufacture materials and chemicals using engineered organisms rather than fossil fuels,\u201d he says. \u201cThat has massive implications\u2014not just for IP, but for the planet.\u201d&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Inside GJE: Collaboration, Clarity, and Client Focus<\/strong>&nbsp;<\/h2>\n\n\n\n<p>Ross describes <a href=\"https:\/\/www.gje.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Gill Jennings &amp; Every<\/a> as a firm where collaboration and adaptability are central to the culture. \u201cIt\u2019s not a siloed environment\u2014we build cross-disciplinary teams to match our clients\u2019 evolving technologies,\u201d he explains. That flexibility is especially valuable in a sector where biotech increasingly intersects with AI, diagnostics, and chemistry.&nbsp;<\/p>\n\n\n\n<p>This approach has helped GJE earn double gold recognition in the IAM Patent 1000 rankings. Ross attributes that success to the firm\u2019s emphasis on clarity, commercial awareness, and strong client relationships. \u201cWe focus on practical advice, not just legal precision. We aim to become a real extension of our clients\u2019 teams.\u201d&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Beyond the Office<\/strong>&nbsp;<\/h2>\n\n\n\n<p>When he\u2019s not helping clients navigate patent law, Ross enjoys life with his young family, reading a mix of sci-fi and science history, and keeping fit. He&#8217;s also an advocate of internal knowledge sharing at GJE, from legal updates to seminars on new biotech tools\u2014ensuring both the law and the science stay front of mind.&nbsp;<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Connect with Ross<\/strong>&nbsp;<\/h2>\n\n\n\n<p>\ud83d\udd17 <a href=\"https:\/\/www.linkedin.com\/in\/rosscummingsgje\/\" target=\"_blank\" rel=\"noreferrer noopener\">Connect with Ross Cummings on LinkedIn<\/a>&nbsp;<br>\ud83c\udfe2 <a href=\"https:\/\/www.gje.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Find out more about Gill Jennings &amp; Every<\/a>&nbsp;<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n\n\n\n<p><strong>P.S.<\/strong> <em><a href=\"https:\/\/patworld.com\/gb\/\">PatWorld<\/a> supports IP professionals like Ross by providing tailored reports that make navigating complex patent landscapes more efficient and informed. Whether it\u2019s freedom-to-operate (FTO) searches, invalidity assessments, or in-depth landscape reports, <a href=\"https:\/\/patworld.com\/gb\/\">PatWorld<\/a> delivers actionable insights across a wide range of technologies. From global trend analysis to highly focused data sets, our support helps attorneys stay ahead of the curve.<\/em>&nbsp;<\/p>\n\n\n\n<p><em>The data visualisations referenced in this article were created by <\/em><a href=\"https:\/\/www.linkedin.com\/in\/geraint-james-307117101\/\" target=\"_blank\" rel=\"noreferrer noopener\"><em>Geraint James<\/em><\/a><em>, Senior IP Manager at <a href=\"https:\/\/patworld.com\/gb\/\">PatWorld<\/a>, using the Questel platform.<\/em>&nbsp;<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>At the forefront of biotech patenting and innovation sits Ross Cummings, a partner at Gill Jennings &amp; Every LLP (GJE), whose career has been shaped by scientific rigor, a deep commitment to clients, and a passion for future-forward technologies. With a PhD in molecular biology from the London School of Hygiene and Tropical Medicine and [&hellip;]<\/p>\n","protected":false},"author":29,"featured_media":3210,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[339,1],"tags":[414,281,263,245,48,413],"class_list":["post-3207","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-meet-the-ip-professional","category-news","tag-gill-jennings-every","tag-innovation-2","tag-life-sciences","tag-patent-attorney","tag-patents","tag-ross-cummings"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ross Cummings: Leading Biotech Patent Innovation at GJE<\/title>\n<meta name=\"description\" content=\"Discover how Ross Cummings, a partner at GJE, drives biotech patent innovation in cellular immunotherapy and RNA technologies, shaping the future of life sciences IP.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ross Cummings: Leading Biotech Patent Innovation at GJE\" \/>\n<meta property=\"og:description\" content=\"Discover how Ross Cummings, a partner at GJE, drives biotech patent innovation in cellular immunotherapy and RNA technologies, shaping the future of life sciences IP.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/\" \/>\n<meta property=\"og:site_name\" content=\"PatWorld GB\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-23T08:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-05T15:41:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/RMC-Headshot-July-2025-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"2560\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mparry\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"mparry\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/news\\\/ross-cummings-biotech-patent-innovation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/news\\\/ross-cummings-biotech-patent-innovation\\\/\"},\"author\":{\"name\":\"mparry\",\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/#\\\/schema\\\/person\\\/6cf7e0c8227a4e1a8de33d8a821549fe\"},\"headline\":\"Meet the IP Professional: Ross Cummings \u2013 Leading the Charge in Life Sciences Innovation\u00a0\",\"datePublished\":\"2025-07-23T08:30:00+00:00\",\"dateModified\":\"2026-01-05T15:41:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/news\\\/ross-cummings-biotech-patent-innovation\\\/\"},\"wordCount\":963,\"image\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/news\\\/ross-cummings-biotech-patent-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/patworld.com\\\/gb\\\/wp-content\\\/uploads\\\/sites\\\/12\\\/RMC-Headshot-July-2025-scaled.jpg\",\"keywords\":[\"Gill Jennings &amp; Every\",\"Innovation\",\"Life Sciences\",\"Patent Attorney\",\"patents\",\"Ross Cummings\"],\"articleSection\":[\"Meet the IP Professional\",\"News\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/news\\\/ross-cummings-biotech-patent-innovation\\\/\",\"url\":\"https:\\\/\\\/patworld.com\\\/gb\\\/news\\\/ross-cummings-biotech-patent-innovation\\\/\",\"name\":\"Ross Cummings: Leading Biotech Patent Innovation at GJE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/news\\\/ross-cummings-biotech-patent-innovation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/news\\\/ross-cummings-biotech-patent-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/patworld.com\\\/gb\\\/wp-content\\\/uploads\\\/sites\\\/12\\\/RMC-Headshot-July-2025-scaled.jpg\",\"datePublished\":\"2025-07-23T08:30:00+00:00\",\"dateModified\":\"2026-01-05T15:41:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/#\\\/schema\\\/person\\\/6cf7e0c8227a4e1a8de33d8a821549fe\"},\"description\":\"Discover how Ross Cummings, a partner at GJE, drives biotech patent innovation in cellular immunotherapy and RNA technologies, shaping the future of life sciences IP.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/news\\\/ross-cummings-biotech-patent-innovation\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/patworld.com\\\/gb\\\/news\\\/ross-cummings-biotech-patent-innovation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/news\\\/ross-cummings-biotech-patent-innovation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/patworld.com\\\/gb\\\/wp-content\\\/uploads\\\/sites\\\/12\\\/RMC-Headshot-July-2025-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/patworld.com\\\/gb\\\/wp-content\\\/uploads\\\/sites\\\/12\\\/RMC-Headshot-July-2025-scaled.jpg\",\"width\":1920,\"height\":2560},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/news\\\/ross-cummings-biotech-patent-innovation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/patworld.com\\\/gb\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Meet the IP Professional: Ross Cummings \u2013 Leading the Charge in Life Sciences Innovation\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/#website\",\"url\":\"https:\\\/\\\/patworld.com\\\/gb\\\/\",\"name\":\"PatWorld GB\",\"description\":\"Global IP Research Services\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/patworld.com\\\/gb\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/patworld.com\\\/gb\\\/#\\\/schema\\\/person\\\/6cf7e0c8227a4e1a8de33d8a821549fe\",\"name\":\"mparry\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7f1e585ae99217b30ad329a862b6beb7e59399547f27169412e2bb0d58112922?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7f1e585ae99217b30ad329a862b6beb7e59399547f27169412e2bb0d58112922?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7f1e585ae99217b30ad329a862b6beb7e59399547f27169412e2bb0d58112922?s=96&d=mm&r=g\",\"caption\":\"mparry\"},\"url\":\"https:\\\/\\\/patworld.com\\\/gb\\\/news\\\/author\\\/mparry\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ross Cummings: Leading Biotech Patent Innovation at GJE","description":"Discover how Ross Cummings, a partner at GJE, drives biotech patent innovation in cellular immunotherapy and RNA technologies, shaping the future of life sciences IP.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/","og_locale":"en_GB","og_type":"article","og_title":"Ross Cummings: Leading Biotech Patent Innovation at GJE","og_description":"Discover how Ross Cummings, a partner at GJE, drives biotech patent innovation in cellular immunotherapy and RNA technologies, shaping the future of life sciences IP.","og_url":"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/","og_site_name":"PatWorld GB","article_published_time":"2025-07-23T08:30:00+00:00","article_modified_time":"2026-01-05T15:41:09+00:00","og_image":[{"width":1920,"height":2560,"url":"https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/RMC-Headshot-July-2025-scaled.jpg","type":"image\/jpeg"}],"author":"mparry","twitter_card":"summary_large_image","twitter_misc":{"Written by":"mparry","Estimated reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/#article","isPartOf":{"@id":"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/"},"author":{"name":"mparry","@id":"https:\/\/patworld.com\/gb\/#\/schema\/person\/6cf7e0c8227a4e1a8de33d8a821549fe"},"headline":"Meet the IP Professional: Ross Cummings \u2013 Leading the Charge in Life Sciences Innovation\u00a0","datePublished":"2025-07-23T08:30:00+00:00","dateModified":"2026-01-05T15:41:09+00:00","mainEntityOfPage":{"@id":"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/"},"wordCount":963,"image":{"@id":"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/RMC-Headshot-July-2025-scaled.jpg","keywords":["Gill Jennings &amp; Every","Innovation","Life Sciences","Patent Attorney","patents","Ross Cummings"],"articleSection":["Meet the IP Professional","News"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/","url":"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/","name":"Ross Cummings: Leading Biotech Patent Innovation at GJE","isPartOf":{"@id":"https:\/\/patworld.com\/gb\/#website"},"primaryImageOfPage":{"@id":"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/#primaryimage"},"image":{"@id":"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/RMC-Headshot-July-2025-scaled.jpg","datePublished":"2025-07-23T08:30:00+00:00","dateModified":"2026-01-05T15:41:09+00:00","author":{"@id":"https:\/\/patworld.com\/gb\/#\/schema\/person\/6cf7e0c8227a4e1a8de33d8a821549fe"},"description":"Discover how Ross Cummings, a partner at GJE, drives biotech patent innovation in cellular immunotherapy and RNA technologies, shaping the future of life sciences IP.","breadcrumb":{"@id":"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/#primaryimage","url":"https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/RMC-Headshot-July-2025-scaled.jpg","contentUrl":"https:\/\/patworld.com\/gb\/wp-content\/uploads\/sites\/12\/RMC-Headshot-July-2025-scaled.jpg","width":1920,"height":2560},{"@type":"BreadcrumbList","@id":"https:\/\/patworld.com\/gb\/news\/ross-cummings-biotech-patent-innovation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/patworld.com\/gb\/"},{"@type":"ListItem","position":2,"name":"Meet the IP Professional: Ross Cummings \u2013 Leading the Charge in Life Sciences Innovation\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/patworld.com\/gb\/#website","url":"https:\/\/patworld.com\/gb\/","name":"PatWorld GB","description":"Global IP Research Services","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/patworld.com\/gb\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/patworld.com\/gb\/#\/schema\/person\/6cf7e0c8227a4e1a8de33d8a821549fe","name":"mparry","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/7f1e585ae99217b30ad329a862b6beb7e59399547f27169412e2bb0d58112922?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7f1e585ae99217b30ad329a862b6beb7e59399547f27169412e2bb0d58112922?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f1e585ae99217b30ad329a862b6beb7e59399547f27169412e2bb0d58112922?s=96&d=mm&r=g","caption":"mparry"},"url":"https:\/\/patworld.com\/gb\/news\/author\/mparry\/"}]}},"_links":{"self":[{"href":"https:\/\/patworld.com\/gb\/wp-json\/wp\/v2\/posts\/3207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/patworld.com\/gb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/patworld.com\/gb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/patworld.com\/gb\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/patworld.com\/gb\/wp-json\/wp\/v2\/comments?post=3207"}],"version-history":[{"count":0,"href":"https:\/\/patworld.com\/gb\/wp-json\/wp\/v2\/posts\/3207\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/patworld.com\/gb\/wp-json\/wp\/v2\/media\/3210"}],"wp:attachment":[{"href":"https:\/\/patworld.com\/gb\/wp-json\/wp\/v2\/media?parent=3207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/patworld.com\/gb\/wp-json\/wp\/v2\/categories?post=3207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/patworld.com\/gb\/wp-json\/wp\/v2\/tags?post=3207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}